Sept 19 (Reuters) - The European Medicines Agency backed

the use of Novo Nordisk's Wegovy in patients with an

obesity-related heart condition, the Danish drugmaker said on

Thursday.

The company expects the EU label update for expanded use of

Wegovy will be implemented shortly. The update will allow the

drug to be given to patients suffering from obesity-related

heart failure with preserved ejection fraction (HFpEF).

The update is based on data from late-stage studies in which

Wegovy helped reduce symptoms of the disease and improved

physical limitations and exercise function in patients.

Earlier this year, the EU regulator also backed use of

Wegovy to lower major heart risks and strokes in overweight or

obese adults without diabetes.